The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Mar 2016 10:34

RNS Number : 0284T
Hutchison China Meditech Limited
23 March 2016
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Hutchison China MediTech Limited

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Change in total voting rights of the issuer

ü

3. Full name of person(s) subject to thenotification obligation: iii

Hutchison Healthcare Holdings Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

22 March 2016

6. Date on which issuer notified:

22 March 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

64%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

36,666,667

36,666,667

36,666,667

36,666,667

60.82

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

36,666,667

60.82%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Hutchison Healthcare Holdings Limited is a wholly owned subsidiary of Hutchison Whampoa (China) Limited, which is an indirect wholly-owned subsidiary of CK Hutchison Holdings Limited - 36,666,667 ordinary shares (60.82%)

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Edith Shih

15. Contact telephone number:

+852 2128 1232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOURRNVAOUAR
Date   Source Headline
17th Nov 20207:00 amRNSUS$100m Equity Investment by CPP Investments
5th Nov 20209:00 amRNSChi-Med to Present HMPL-689 Clinical Data at ASH
30th Oct 202012:00 pmRNSChi-Med to Attend Upcoming Conferences
30th Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20207:00 amRNSTotal Voting Rights
21st Sep 20207:00 amRNSSurufatinib Data at ESMO and in Lancet Oncology
17th Sep 202011:45 amRNSSecond Chinese NDA Acceptance for Surufatinib
4th Sep 20207:00 amRNSChi-Med Initiates Global Phase III Trial
3rd Sep 20207:00 amRNSChi-Med Initiates a Phase II Trial
28th Aug 202011:30 amRNSTotal Voting Rights
24th Aug 20207:00 amRNSClinical Data to be Presented at ESMO 2020
12th Aug 202010:30 amRNSGrant of Share Options under Share Option Scheme
10th Aug 20207:00 amRNSSurufatinib Marketing Authorization Application
30th Jul 202012:00 pmRNSInterim Results and Clinical Update
30th Jul 20207:00 amRNSBlock Admission Application
28th Jul 20207:00 amRNSChi-Med & Lilly Collaborate on Elunate in China
28th Jul 20207:00 amRNSSavolitinib NDA Granted Priority Review in China
24th Jul 20207:00 amRNSChi-Med Initiates HMPL-306 Phase I Trial in China
8th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSNotification of Dilution of Voting Rights
29th Jun 20207:00 amRNSBlocklisting Six Monthly Return
26th Jun 20207:00 amRNSNotice of Results
25th Jun 20207:15 amRNS$100 Million Equity Investment by General Atlantic
18th Jun 20208:15 amRNSFruquintinib Granted US FDA Fast Track Designation
9th Jun 20207:00 amRNSUS$95m Guangzhou Land Compensation Agreement
4th Jun 20207:00 amRNSContinuation of Phase III FRUTIGA Study
2nd Jun 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:37 pmRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSChi-Med Plans to Submit US NDA for Surufatinib
29th May 20201:00 pmRNSChi-Med to Discuss Data Presented at ASCO20
29th May 20207:00 amRNSNDA Acceptance in China for Savolitinib
26th May 20207:00 amRNSChi-Med and BeiGene Enter Clinical Collaboration
14th May 20207:00 amRNSClinical Data to be Presented at ASCO20
11th May 20204:41 pmRNSSecond Price Monitoring Extn
11th May 20204:36 pmRNSPrice Monitoring Extension
11th May 20207:00 amRNSChi-Med to Attend Upcoming Investor Conferences
29th Apr 202011:45 amRNSGrant of Share Options under Share Option Scheme
27th Apr 20202:00 pmRNSResult of AGM
22nd Apr 20209:00 amRNSVirtual Presentations of Surufatinib at AACR
21st Apr 202011:30 amRNSGrant of LTIP Awards and Share Options
17th Apr 20207:00 amRNSSurufatinib Granted FDA Fast Track Designations
31st Mar 20207:04 amRNSChina Phase II trial initiation in mesothelioma
25th Mar 20207:00 amRNSAnnual Financial Report
9th Mar 20207:00 amRNSVesting of awards under Long Term Incentive Plan
3rd Mar 20202:18 pmRNSForm-20F Publication
3rd Mar 202012:15 pmRNSFinal Results and Clinical Update
25th Feb 20207:00 amRNSNotice of Results
10th Feb 20207:00 amRNSPhase II Savolitinib / Imfinzi® Combination Data
6th Feb 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.